Nivolumab-induced radiation recall pneumonitis in non-small-cell lung cancer patients with thoracic radiation therapy

被引：2

作者：

Noda-Narita, Shoko ^{[1
]}

Naito, Tomoyuki ^{[2
]}

Udagawa, Hibiki ^{[2
]}

Goto, Koichi ^{[2
]}

Miyawaki, Taichi ^{[3
]}

Mamesaya, Nobuaki ^{[3
]}

Nakashima, Kazuhisa ^{[3
]}

Kenmotsu, Hirotsugu ^{[3
]}

Shimokawaji, Tadasuke ^{[4
]}

Kato, Terufumi ^{[4
]}

Hakozaki, Taiki ^{[5
]}

Okuma, Yusuke ^{[5
]}

Nakamura, Masaki ^{[6
]}

Nakayama, Yuko ^{[7
]}

Watanabe, Hirokazu ^{[8
]}

Kusumoto, Masahiko ^{[8
]}

Ohe, Yuichiro ^{[1
]}

Horinouchi, Hidehito ^{[1
,9
]}

机构：

[1] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[2] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Japan

[3] Shizuoka Canc Ctr, Dept Thorac Oncol, Shizuoka, Japan

[4] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Japan

[5] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan

[6] Natl Canc Ctr Hosp East, Dept Radiat Oncol, Kashiwa, Japan

[7] Natl Canc Ctr, Dept Radiat Oncol, Tokyo, Japan

[8] Natl Canc Ctr, Dept Diagnost Radiol, Tokyo, Japan

[9] Natl Canc Ctr, Dept Thorac Oncol, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan

来源：

CANCER SCIENCE | 2023年 / 114卷 / 02期

关键词：

antineoplastic agent; carcinoma; immune checkpoint inhibitor; immunological; nivolumab; non-small-cell lung; radiation pneumonitis; INHIBITOR-RELATED PNEUMONITIS; DOCETAXEL; PEMBROLIZUMAB; RADIOTHERAPY; MECHANISMS;

D O I：

10.1111/cas.15621

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The role of previous thoracic radiation therapy as a risk factor of immune-related pneumonitis is unclear. Furthermore, some patients develop radiation recall pneumonitis, which is characterized by a radiation pneumonitis-like imaging pattern with consolidation progressing within a previous radiation field. In this multicenter retrospective study, we analyzed the relationship of previous thoracic radiation therapy with immune-related pneumonitis and the characteristics of radiation recall pneumonitis. The medical records of patients with non-small-cell lung cancer who had received nivolumab between December 2015 and March 2017 at five institutions were retrospectively reviewed. Incidence, imaging patterns, clinical course, and risk factors of immune-related pneumonitis and radiation recall pneumonitis were evaluated. A total of 669 patients were evaluated, and the incidences of all-grade and grade 3 or higher immune-related pneumonitis were 8.8% and 2.6%, respectively. The incidences of immune-related pneumonitis were 13.2% (34/257) and 6.1% (25/412) in patients with and those without previous thoracic radiation therapy, respectively. A history of previous thoracic radiation therapy was associated with immune-related pneumonitis (odds ratio, 2.11; 95% confidence interval, 1.21-3.69 in multivariate analysis). Among the patients with previous thoracic radiation therapy, 6.2% (16/257) showed radiation recall pattern. This study found an increased risk of nivolumab-induced immune-related pneumonitis associated with a history of thoracic radiation therapy. Radiation recall pattern was one of the major patterns of immune-related pneumonitis among the patients with previous thoracic radiation therapy. Incidence, risk factors, and clinical outcome of radiation recall pneumonitis were elucidated.

引用

页码：630 / 639

页数：10

共 20 条

[1] The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence [J].

Barker, Holly E. ;

Paget, James T. E. ;

Khan, Aadil A. ;

Harrington, Kevin J. .

NATURE REVIEWS CANCER, 2015, 15 (07) :409-425

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[4] Characteristics, incidence, and risk factors of immune checkpoint inhibitor related pneumonitis in patients with non-small cell lung cancer [J].

Cho, Jun Yeun ;

Kim, Junghoon ;

Lee, Jong Seok ;

Kim, Yu Jung ;

Kim, Se Hyun ;

Lee, Yeon Joo ;

Cho, Young-Jae ;

Yoon, Ho Il ;

Lee, Jae Ho ;

Lee, Choon-Taek ;

Park, Jong Sun .

LUNG CANCER, 2018, 125 :150-156

[5] Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors [J].

Fukihara, Jun ;

Sakamoto, Koji ;

Koyama, Junji ;

Ito, Takayasu ;

Iwano, Shingo ;

Morise, Masahiro ;

Ogawa, Masahiro ;

Kondoh, Yasuhiro ;

Kimura, Tomoki ;

Hashimoto, Naozumi ;

Hasegawa, Yoshinori .

CLINICAL LUNG CANCER, 2019, 20 (06) :442-+

[6] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[7] Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer [J].

Kato, Terufumi ;

Masuda, Noriyuki ;

Nakanishi, Yoichi ;

Takahashi, Masashi ;

Hida, Toyoaki ;

Sakai, Hiroshi ;

Atagi, Shinji ;

Fujita, Shiro ;

Tanaka, Hiroshi ;

Takeda, Koji ;

Satouchi, Miyako ;

Namba, Yoshinobu ;

Tamura, Tomohide .

LUNG CANCER, 2017, 104 :111-118

[8] Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis [J].

Nishino, Mizuki ;

Giobbie-Hurder, Anita ;

Hatabu, Hiroto ;

Ramaiya, Nikhil H. ;

Hodi, Stephen .

JAMA ONCOLOGY, 2016, 2 (12) :1607-1616

[9] Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer [J].

Ohe, Yuichiro ;

Ichinose, Yukito ;

Nakagawa, Kazuhiko ;

Tamura, Tomohicle ;

Kubota, Kaoru ;

Yamamoto, Nobuyuki ;

Adachi, Susumu ;

Nambu, Yoshihiro ;

Fujimoto, Toshio ;

Nishiwaki, Yutaka ;

Saijo, Nagahiro ;

Fukuoka, Masahiro .

CLINICAL CANCER RESEARCH, 2008, 14 (13) :4206-4212

[10] Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer [J].

Paz-Ares, L. ;

Luft, A. ;

Vicente, D. ;

Tafreshi, A. ;

Gumus, M. ;

Mazieres, J. ;

Hermes, B. ;

Senler, F. Cay ;

Csoszi, T. ;

Fulop, A. ;

Rodriguez-Cid, J. ;

Wilson, J. ;

Sugawara, S. ;

Kato, T. ;

Lee, K. H. ;

Cheng, Y. ;

Novello, S. ;

Halmos, B. ;

Li, X. ;

Lubiniecki, G. M. ;

Piperdi, B. ;

Kowalski, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2040-2051

← 1 2 →